ArticleThe Journal of experimental medicine1998
Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis.
Article in The Journal of experimental medicine, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 58 citations in OpenAlex.
- Membranous nephropathy: Clearer pathology and mechanisms identify potential strategies for treatment.Frontiers in immunology · 2022Review
- Mechanisms of Primary Membranous Nephropathy.Biomolecules · 2021Review
- Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury.Antioxidants (Basel, Switzerland) · 2021Review
- Unmet challenges in membranous nephropathy.Current opinion in nephrology and hypertension · 2019Review
- The Modified Vaccination Technique.Vaccines · 2018Article
- Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency.Journal of the American Society of Nephrology : JASN · 2016Article
- Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy.Frontiers in immunology · 2016Review
- Membranous nephropathy: from models to man.The Journal of clinical investigation · 2014Review
- Complement regulation in renal disease models.Seminars in nephrology · 2013Review
- The role of complement in membranous nephropathy.Seminars in nephrology · 2013Review
- CD8+ regulatory T cells induced by T cell vaccination protect against autoimmune nephritis.Journal of the American Society of Nephrology : JASN · 2012Article
- Experimental membranous nephropathy redux.American journal of physiology. Renal physiology · 2005Review
- Mechanisms of immune-deposit formation and the mediation of immune renal injury.Clinical and experimental nephrology · 2005Review
- Complement regulation during pregnancy.Immunologic research · 2005Review
- Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model.International journal of experimental pathology · 2004Article
- Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats.International journal of experimental pathology · 2004Article
- Production of a new model of slowly progressive Heymann nephritis.International journal of experimental pathology · 2003Article
- Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris.Immunology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Crry (complement receptor 1-related protein/gene y) is a key cellular complement regulator in rodents. It is also present in Fx1A, the renal tubular preparation used to immunize rats to induce active Heymann nephritis (HN), a model of membranous nephropathy. We hypothesized that rats immunized with anti-Fx1A develop autoantibodies (auto-Abs) to Crry as well as to the megalin-containing HN antigenic complex, and that anti-Crry Abs promote the development of injury in HN by neutralizing the complement regulatory activity of Crry. Rats immunized with Fx1A lacking Crry remained free of proteinuria and glomerular deposits of C3 during a 10-wk follow-up despite typical granular immunoglobulin (Ig)G deposits in glomeruli. Anti-Fx1A auto-Abs were present in their sera at levels that were not different from sera pooled from proteinuric rats with HN induced with nephritogenic Fx1A. Passive administration of sheep anti-Crry Abs to rats immunized with Crry-deficient Fx1A led to proteinuria and glomerular C3 deposition, which were not seen in such rats injected with preimmune IgG, nor in rats with collagen-induced arthritis injected with anti-Crry IgG. To directly examine the role of Crry in HN, rats were immunized with Crry-deficient Fx1A reconstituted with rCrry. This led to typical HN, with 8 out of 15 rats developing proteinuria within 14 wk. Moreover, the extent of glomerular C3 deposition correlated with proteinuria, and anti-Crry Abs were present in glomerular eluates. Thus, Crry is a key nephritogenic immunogen in Fx1A. Formation of neutralizing auto-Abs to Crry impairs its function, leading to unrestricted complement activation by Abs reactive with the HN antigenic complex on the epithelial cell surface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.